HotSpot Therapeutics Acquires Macroceutics
Summary
HotSpot Therapeutics, Inc., a Boston, MA-based biotechnology company advancing the discovery of nature’s regulatory sites to advance allosteric drug discovery, acquired Macroceutics, Inc., a provider of DNA-encoded library (DEL) screening technologies. As part of the transcation, the company will be able to leverage approximately 1 billion custom drug-like molecules, the company’s full suite of DNA-based chemistries, and a fully enabled screening platform. Led by Geraldine Harriman, PhD, Co-Founder and Chief Scientific Officer, HotSpot Therapeutics is targeting nature’s regulatory mechanisms to create allosteric medicines that exhibit high precision and potency. The company leverages its proprietary SpotFinder™ technology, a platform designed to identify “regulatory hotspots,” a unique family of pockets that sit remote from the active site on a protein and are used by nature to control protein function. Its lead compounds include the first and only allosteric inhibitors to target PKC-theta for autoimmune diseases, and S6 kinase, an immuno-metabolic enzyme involved in the regulation of hepatic insulin sensitivity and mitochondrial function – an important new target for NASH and metabolic diseases.